Japan has made history by granting the world’s first conditional approvals for stem cell regenerative therapies treating Parkinson’s disease and severe heart failure in 2026.
The Parkinson’s treatment transplants lab grown dopamine producing cells into the brain, while the heart therapy uses muscle cell sheets to restore cardiac function. Both approvals allow real world use while further safety data is collected. This marks a major leap for regenerative medicine worldwide. Stay updated on breakthroughs transforming modern healthcare. 
–
.
.
.
.
